<DOC>
	<DOC>NCT02079324</DOC>
	<brief_summary>The purpose of this research is to evaluate MTD, Safety and efficacy of GX-051 after intratumoral injection in head and neck cancer patience.</brief_summary>
	<brief_title>Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer</brief_title>
	<detailed_description>The primary purpose of the study is to determine MTD(Maximum Tolerable Dose) of GX-051 administered in tumor. The second purpose is to evaluate safety and efficacy of GX-051.</detailed_description>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Are capable of understanding and complying with the requirements of the study and have signed the informed consent from (ICF). Very advanced head and neck cancer aged more than 19. Longest distance of the tumor is bigger than 1 cm and capable of Intratumoral injection. Baseline ECOG Performance Status 0, 1 or 2. Have a life expectancy more than 6 months. Have no history of prior anticancer treatment. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.Subject who have participated in a clinical trial of an treatment vaccine or immunotherapy in an year. Have a tumor which is near a main vessel that can be occured embolism after injection or which has hypervascularity. Patients currently receiving anticancer immunotherapies Patients who have received prior treatment with an stem cell therapy. Have autoimmune disease (multiple sclerosis, systemic lupus erythromatosis, thyroiditis, psoriasis, inflammatory bowel diseases etc.). Have Graft rejection reaction such as GVHD. Have immunodeficiency disease. Leukocytes&lt; 3.0 x109/L. Absolute neutrophil count &lt; 1.5x109/L. Platelet count &lt; 100 x 109/L. Have known positive test for hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV). Alanine Aminotransferase (ALT) &gt; 2.5xUNL. Aspartate Aminotransferase (AST)&gt; 2.5xUNL. Total Bilirubin&gt; UNL. Have blood Creatinine&gt; UNL. Known allergy to IL12 or the excipient(s) of the study medication including fetal bovine serum. Second primary cancer Metastatic brain tumor or meningioma. Have a tumor near a main artery. Uncontrolled hypertension. Uncontrolled diabetes uncontrolled (arrhythmia). Heart failure (more than NYHA Functional Class II); unstable coronary artery disease; myocardial infarction within 6 months. ChildPugh Class C hepatic impairment. Severe renal impairment (creatinine clearance &lt; 30 ml/min) or on dialysis. Have active infection or history of recurrent infection. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study. Are considered ineligible by the investigator due to a mental disease or CNS disease. Administration of any other tumor therapy, including chemotherapy and radiotherapy within 4 weeks(6 weeks in case of nitrosoureas and mytomycin C) before the beginning of study treatment. Patients receiving chronic, systemic treatment with immunosuppressive agent(steroid) or immunomodulator within 2 weeks prior to screening. Have participated in another clinical trial within 30 days prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>head and neck cancer</keyword>
	<keyword>gene therapy</keyword>
	<keyword>stem cell therapy</keyword>
	<keyword>immunotherappy</keyword>
</DOC>